Tai Sandi See - 18 Nov 2025 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Reporting relationship: Chief Development Officer
Issuer ticker: LXEO
Reported as of: 18 Nov 2025
Net transaction value: -$3,578
SEC form: 4
Accepted by SEC: 20 Nov 2025, 17:19:10 UTC
Prior SEC filing: 17 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Youjin Choi, Attorney-in-Fact

Key filing fact

Tai Sandi See filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 20 Nov 2025.

Key facts

This page summarizes Tai Sandi See's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Nov 2025, 17:19.

Change

Previous filing in this sequence was filed on 17 Oct 2025.
Current net transaction value: -$3,578.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002009350 Primary reporting owner

See Tai Sandi

Relationship: Chief Development Officer
Address: C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK
Signature: /s/ Youjin Choi, Attorney-in-Fact
Signature date: 20 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXEO transaction

Common Stock

Sale

Transaction value: $3,578
Shares: -386
Change %: -0.59%
Price: $9.27
Shares after: 65,476
Date: 18 Nov 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

Footnote F2

This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

Includes 48,098 RSUs.